Gilead's Sofosbuvir for Hepatitis C M...

Gilead's Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study

There are 1 comment on the Drugs.com story from Feb 19, 2013, titled Gilead's Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study. In it, Drugs.com reports that:

Feb 19, 2013 - Gilead Sciences today announced topline results from the Phase 3 FUSION study evaluating 12- and 16-week courses of therapy with the once-daily nucleotide sofosbuvir plus ribavirin in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus infection who failed prior treatment.

Join the discussion below, or Read more at Drugs.com.

Axel

Bucharest, Romania

#1 Feb 19, 2013
Thank God, thank God and good doctors

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Health Discussions

Title Updated Last By Comments
News Are depressed kids bully magnets? (Feb '12) 2 hr gmail sign in 40
News CDC forced to reveal documents proving Thimeros... 3 hr friend 1
News Pregnancy Symptoms - 12 Very Early Symptoms of ... (Jun '07) 4 hr Hayla 6,823
News Why US smoking rates are declining faster than ... 5 hr Pete 1
Cardiovascular Health 9 hr uach 1
News Smoking may increase kidney disease risk in Afr... 9 hr Drilling for the ... 9
News The autism epidemic is rising steadily in Ameri... 12 hr friend 12
More from around the web